GDRX 最新10-Q变化
将 GDRX 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-05 与上一份 10-Q · 2026-05-06
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +70 | −39 | ~21 | 172 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 2 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 13 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 2 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 3 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-05
quarter. Monthly Active Consumers from acquired companies are included beginning from the acquisition date.
Companion which launched its monthly and annual plans in May and July 2026, respectively. References to
second quarter of 2026, a new subscription offering that provides consumers access to free and low-cost generic
medications, affordable online care visits, and savings on routine healthcare services.
material impact on our business to date. In May 2026, an expansion of TrumpRx was announced to include more than 600
相对上期删除的文字 · 来源:10-Q · 2026-05-06
quarter. Effective January 1, 2025, Monthly Active Consumers from acquired companies are included
of TrumpRx on our business, offerings, or results of operations remains uncertain and could be material. With the
introduction of these federal initiatives, including the renewed focus on Most-Favored-Nation pricing, the market is shifting
decisively toward greater transparency and direct-to-consumer access. For us, this evolution is both an opportunity and a
and pharmacy economics, including the growing relevance of self-pay and direct-to-consumer distribution models, we are
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议